HESS-STUMP HOLGER
No ORCID on file
· 18 papers in corpus
· active 2001-2007
Frequent coauthors
- ZORN LUDWIG 12
- HUTH ANDREAS 12
- KRUEGER MARTIN 12
- MENRAD ANDREAS 12
- THIERAUCH KARL-HEINZ 12
- HABEREY Martin 12
- INCE STUART 12
- HAENDLER Bernard 6
- CHWALISZ Kristof 6
- LESSEY Bruce 6
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2001
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2001
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2001
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.